Jefferies said AstraZeneca and Ionis's trial setback could clear the way for BridgeBio's ATTR-CM drug, while Alnylam rose 2.4% as Amvuttra stayed the only gene silencer for the disease.
verifying reliability
No specialized terms available for this topic.